Photo courtesy of NTF Against Covid-19 MANILA - Local pharmaceutical firm Lloyd Laboratories Inc. (LLI) is eyeing a "fill and finish" operation for a new Chinese vaccine against coronavirus disease (Covid-19) that is still undergoing clinical trials. In a virtual media interview Thursday, LLI medical consultant Dr. Antonio Ligsay said the company has partnered with Livzon Biotech's Livzon Mabpharm, Inc. for the phase three clinical trial of the V-01, a code name for the recombinant vaccine against Covid-19. Ligsay said the interim analysis will be concluded by the end of this month. "Hopefully, our results will be good towards the end of the month, and if it's good, then we will apply for EUA (emergency use authorization)," he added. Ligsay said V-01's phases one and two were conducted in China and the third phase was conducted in the Philippines, Indonesia, and Russia with a total of 21,500 respondents. The Philippines has the largest number of subjects